Metastatic prostate cancer
Prof Shingai Mutambirwa gives us a better notion of what metastatic prostate cancer is and the outcomes of the various metastases.
What is metastatic prostate cancer?
When cancer cells from the prostate enter the blood and lymph vesselsĀ and travel to other parts of the body where they re-implant and growĀ to form secondary tumours or metastases, this is called metastatic prostate cancer or Stage IV.Ā
At this advanced stage, the cancerĀ is unfortunately no longer curableĀ but can be contained for a periodĀ on appropriate therapies. The 5-year cancer specific survival for men diagnosed with metastatic prostate cancer hovers between 30-40%.Ā
Various studies have shown that men who present with prostateĀ cancer (PC) symptoms at South African public hospitals often have advanced disease. This may be dueĀ to a lack of awareness about age-appropriate screening; a lack of access to screening; or a lack of awarenessĀ of PC itself. Awareness and screening is important as early stage prostate cancer, which almost exclusively can only be found by screening, is curable in up to 95% of men.
Treatments goals
The standard initial treatment is known as androgen deprivationĀ therapy (ADT) and involves removing testosterone from the body to slowĀ the progression of the disease.Ā
Unfortunately, most advanced prostate cancers treated with ADTĀ will eventually become resistant toĀ the treatment after about two years and the cancer will start to progress again. This is called castrate resistant prostate cancer (CRPC).Ā
PC most commonly spreads to bone. Other sites that are typically affected are distant lymph nodes, liver and lungs. It can spread to any organ inĀ the body but this is rare and occursĀ in <5% of patients.
Involvement of lymph nodesĀ
The lymphatic system consists of lymph vessels, lymph nodes and two collecting ducts and is part of the bodyās immune system. The lymph vessels carry lymph fluid, which contains nutrients and other substances, which are returned via drainage into the bloodstream to circulate back to the rest of the body. Lymph vessels also remove and transport damaged cells, cancer cells, bacteria and viruses that drain from tissue. These are then filtered outĀ when the lymph fluid travels through the lymph nodes.
PC tends to spread to regional lymph nodes in the pelvic area first. This isnāt classified as metastatic disease and has a better prognosis.
If PC spreads to lymph nodes outside the pelvic area (distant lymph nodes), itās classified as one of the sites for distant metastases.Ā
Bone metastasesĀ
PC cells have a strong affinity to spread to bone. PC cells tend to spread first to the lower spine and pelvic bone and then up the spine and to the ribs.
The cancer cells interact with the different types of bone cells. Most commonly the interaction is with the boneās ābuilder cellsā (osteoblasts), resulting in an abnormal build-up of bone. Less commonly the interactionĀ is with the boneās ādemolisher cellsā (osteoclasts), resulting in soft sections of damaged bone. Both cause bone weakness, potential fractures and pain.
Non-lymph nodeĀ visceral metastases
When PC spreads to soft tissue organs other than the lymph nodes, these growths are called visceral metastases.
Men with visceral metastases generally have a worse outcome than men who only have bone metastases. Typical visceral metastatic sites are the lungs and liver which are generally affected in the late stages of PC.Ā
Most men (76%) that develop lung and liver metastases already have bone metastases.Ā
Less common visceral metastatic sites include the brain/meninges, thyroid gland, adrenal glands, peritoneum, gastrointestinal tract, urinary tract, ureter, urethra and kidneys, spleen or pancreas.Ā
Men with liver metastasesĀ tend to have the worst survival outcome compared to men withĀ bone metastases or other sites ofĀ visceral metastases.
Prognosis
Though metastatic prostate cancer isnāt curable, there are numerous therapies including chemotherapy, advanced ADT, genetic therapies and targeted therapies, often involving radiation, that can contain it.
General health measures, suchĀ as exercise and not smoking, also contribute to prolongation of survival. Bone, heart and mental health also need to be addressed and should beĀ a part of both patient and the treating teamās goals.
In addition, other first-degree family members may have an increased risk of developing cancers, particularly breast and prostate and so should be advised for earlier screening at some stage.

MEET THE EXPERT – Prof Shingai Mutambirwa
Prof Shingai Mutambirwa is the Head of Urology at Sefako Makgatho Health Sciences University as well as the chairman of the academic committee of the South African Urological Association and Head of theĀ Medical and Scientific Advisory Board of The Prostate Cancer Foundation of South Africa.
